恩格列净对射血分数降低和保留的心衰患者运动能力和症状的影响
EMPIRIAL-Reduced和EMPIRIAL-Preserved两项试验分别纳入射血分数降低(≤40%,N=312)和保留(>40%,N=315)的心衰患者,随机接受恩格列净10 mg或安慰剂治疗12周。主要终点6分钟步行试验距离变化在两组均无统计学显著性,关键次要终点KCCQ-TSS和CHQ-SAS呼吸困难评分变化亦无显著性。恩格列净耐受性良好,安全性与此前报道一致。
要点
- 恩格列净10 mg治疗12周未显著改善HFrEF或HFpEF患者的6分钟步行距离。
- KCCQ-TSS和CHQ-SAS呼吸困难评分变化无统计学意义。
- HFrEF探索性分析中KCCQ-TSS应答率、淤血评分和利尿剂使用有改善,需进一步验证。
核心结论
- 两项试验的主要终点均为中性,恩格列净未显著改善心衰患者运动能力。
- 恩格列净在伴或不伴2型糖尿病的心衰患者中耐受性良好,安全性与此前报道一致。
- HFrEF探索性分析中观察到假设生成性的次要终点改善。
研究设计与样本
- EMPIRIAL-Reduced和EMPIRIAL-Preserved两项随机对照试验。
- HFrEF患者射血分数≤40%,N=312;HFpEF患者射血分数>40%,N=315。
- 患者随机接受恩格列净10 mg或安慰剂治疗12周。
- 主要终点为第12周6分钟步行试验距离变化。
主要发现
- 第12周6MWTD中位差值(恩格列净vs安慰剂)在EMPIRIAL-Reduced为-4.0米(95%CI -16.0至6.0;P=0.42)。
- 第12周6MWTD中位差值在EMPIRIAL-Preserved为4.0米(95%CI -5.0至13.0;P=0.37)。
- KCCQ-TSS和CHQ-SAS呼吸困难评分变化无统计学显著性。
- HFrEF探索性分析中KCCQ-TSS应答率、淤血评分和利尿剂使用有改善。
关键数值与推荐
- HFrEF定义为射血分数≤40%,HFpEF定义为射血分数>40%。
- 恩格列净剂量为10 mg每日一次,疗程12周。
- 主要终点非显著后,所有次要终点均视为探索性。
临床怎么用
- 恩格列净10 mg在伴或不伴2型糖尿病的心衰患者中耐受性良好。
- 本研究未显示恩格列净12周内改善运动能力,不应据此扩展适应症。
- HFrEF患者中探索性症状改善需进一步研究验证。
局限性
- 主要终点为中性,次要终点均为探索性,结论需谨慎解读。
- 研究持续时间较短(12周),长期效果未知。
- 探索性分析结果仅为假设生成性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). METHODS AND RESULTS: HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were -4.0 m (-16.0, 6.0; P = 0.42) and 4.0 m (-5.0, 13.0; P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported. CONCLUSION: The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.
引用
- Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021. PMID: 33351892. doi:10.1093/eurheartj/ehaa943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。